Evaluation of regulatory T cell and disease activity after transdermal administration of Dovonex(r) ointment 50ug/g in patients with rheumatoid arthritis - Evaluation of regulatory T cell and disease activity after transdermal administration of Dovonex(r) ointment 50ug/g in patients with rheumatoid arthritis

Medical Co.LTA PS Clinic0 sites20 target enrollmentMay 15, 2016

Overview

No summary available.

Registry

who.int

Start Date

May 15, 2016

End Date

September 30, 2016

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Medical Co.LTA PS Clinic

•1, Patients with other systemic autoimmune disease (e.g. systemic erythematosus). 2, Patients with history of hypersensitivity to Calcipotriol. 3, Patients with or with the risk of hypercalcemia, or whose serum calcium level exceed normal range. 4, Patients currently treated with Calcineurin antagonist (Cyclosporine or Tacrolimus). 5, Patients currently treated with anti\-osteoporosis drugs (Vitamin D3, PTH). 6, Patients whose eGFR is 60 or lower. 7, Patients treated for bacterial infection within 30 days prior to the first administration of the study drug. 8, Uncooperative patients who might not comply with the protocol procedure. 9, Patients with malignant tumor requiring treatment within past 5 years. 10, Patients judged inappropriate for this study by principal investigator.